Clinical Trials Logo

Premenopausal Breast Cancer clinical trials

View clinical trials related to Premenopausal Breast Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05982093 Recruiting - Breast Cancer Clinical Trials

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

SOLTI-2104
Start date: October 3, 2023
Phase: Phase 2
Study type: Interventional

PREMIERE parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study in premenopausal women with primary operable HR+/HER2-negative breast cancer with aiming at evaluating the biological effects of elacestrant with or without triptorelin.

NCT ID: NCT05720260 Recruiting - Clinical trials for Metastatic Breast Cancer

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Start date: January 17, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label randomized phase II study in estrogen receptor positive locally advanced or metastatic breast cancer patients. The main inclusion population are either luminal subtype B by PAM50 analysis or failed less than 2 lines of hormonal therapy for locally advanced or metastatic breast cancer. The subjects have to be premenopausal or perimenopausal and are not allowed to receive any systemic chemotherapy for their locally advanced or metastatic breast cancer. Eligible subjects will be randomized into goserelin/ fulvestrant (Arm 1, control), goserelin/ fulvestrant/ durvalumab (Arm 2), goserelin/ fulvestrant/ capivasertib/ durvalumab (Arm 3), or goserelin/ fulvestrant/ capivasertib (Arm 4) at a 1:1:1:1 ratio. The primary endpoint is objective response rate (ORR) of the whole other three arm compared to goserelin/ fulvestrant control arm. The major secondary endpoint will be progression-free survival or ORR compared among different treatment arms.

NCT ID: NCT05333328 Recruiting - Breast Cancer Clinical Trials

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

INTERSTELLAR
Start date: February 6, 2023
Phase: Phase 4
Study type: Interventional

Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.